Apellis Pharmaceuticals, Inc. (APLS) Presents at Stifel 2025 Healthcare Conference Transcript

Core Insights - Apellis is in a strong position with a foundational technology targeting the complement cascade, specifically C3, which is believed to optimally control complement dysregulation [2] - The company has achieved three drug approvals in approximately 3 to 3.5 years, indicating a robust pipeline and growth potential [2] Drug Approvals - The first approval was for EMPAVELI, targeting paroxysmal nocturnal hemoglobinuria [3] - The second approval was for SYFOVRE, which addresses geographic atrophy, received about 2.5 years ago [3] - Recently, EMPAVELI received a second approval for C3G and IC-MPGN, bringing the total indications to four [3]